The Challenge
Genome-wide association studies (GWAS) had strongly linked variants in the FTO gene to obesity risk. FTO was the strongest genetic risk factor for obesity, but the mechanism remained elusive. The variants were in a non-coding intron. The biological question was: Do these non-coding variants regulate FTO expression, or do they bypass FTO to regulate a distant gene?
The Solution
Researchers employed Chromosome Conformation Capture (3C/4C) technology to map the physical interactions of the FTO risk interval. They designed experiments to query the interaction frequency between the FTO enhancer region (harboring the obesity-associated SNVs) and promoters of all neighboring genes in a large genomic window, spanning over 1 Megabase.
The Result
The 3C data revealed a surprising, strong long-range chromatin loop. The FTO enhancer did not interact significantly with the FTO promoter. Instead, it formed a robust physical loop with the promoter of IRX3, a gene located several hundred kilobases away. Furthermore, 3C analysis in human, mouse, and zebrafish models showed this interaction was evolutionarily conserved.
The Conclusion
This validation provided the "smoking gun" evidence that IRX3 (not FTO) was the true effector gene for obesity risk in this locus. This discovery, enabled by 3C technology, shifted the entire paradigm of obesity drug development for this target.
Source: Smemo, S., et al. "Obesity-associated variants within FTO form long-range functional connections with IRX3." Nature (2014). Link to Paper



Figure 1: 3C Library QC Gel
Figure 2: Interaction Frequency Plot